EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Artificial Intelligence in Pulmonary Hypertension: Advancements, Opportunities, and Challenges

Xinyi Li, Linyue Zhang, Li Zhang iD, Yuji Xie, Mingxing Xie iD, Mengmeng Ji iD, Qing He, Zhenni Wu, Shuxuan Qin, Yuman Li

Journal of Clinical Medicine · 07.11.2026 · 15 (21) · 8707

DOI: 10.3390/jcm15218707 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.11.2026. Verfasst von Xinyi Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan …. Die Arbeit nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary hypertension (PH) is a progressive cardiopulmonary disorder associated with high morbidity and mortality. Delayed diagnosis, heterogeneous disease phenotypes, and variable treatment responses remain major clinical challenges. Artificial intelligence (AI), including machine learning and deep learning, has emerged as a promising tool for improving PH management. AI-based models have demonstrated promising performance in screening, diagnosis, classification, risk stratification, and prognosis prediction using multimodal data such as electrocardiography, chest radiography, computed tomography, cardiac magnetic resonance imaging, echocardiography, and electronic health records. Furthermore, AI may support individualized risk assessment, treatment-response prediction, early identification of right ventricular deterioration, and longitudinal remote monitoring. Emerging technologies, including explainable AI, federated learning, large language models, and digital twins, may further advance precision medicine in PH. Despite these advances, data quality, interpretability, privacy, and clinical implementation of AI remain challenges. This review summarizes current applications, opportunities, and challenges of AI in PH and discusses future directions for AI-assisted precision healthcare.

Schlagwörter

Stichwörter der Autor:innen

artificial intelligencedeep learningdiagnosismachine learningpulmonary hypertension

Autor:innen und Institutionen

  • Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China.
  • Clinical Research Center for Medical Imaging in Hubei Province, Wuhan 430022, China.
  • Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.
  • Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan 430022, China.

ORCID-Profile: Li Zhang, Mingxing Xie, Mengmeng Ji

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, X., Zhang, L., Zhang, L., Xie, Y., Xie, M., Ji, M., He, Q., Wu, Z., Qin, S., & Li, Y. (2026). Artificial Intelligence in Pulmonary Hypertension: Advancements, Opportunities, and Challenges. Journal of Clinical Medicine, 15(21), 8707. https://doi.org/10.3390/jcm15218707

Vancouver

Li X, Zhang L, Zhang L, Xie Y, Xie M, Ji M, et al. Artificial Intelligence in Pulmonary Hypertension: Advancements, Opportunities, and Challenges. Journal of Clinical Medicine. 2026;15(21):8707. doi:10.3390/jcm15218707

BibTeX
@article{Li2026,
  author = {Li, Xinyi and Zhang, Linyue and Zhang, Li and Xie, Yuji and Xie, Mingxing and Ji, Mengmeng and He, Qing and Wu, Zhenni and Qin, Shuxuan and Li, Yuman},
  title = {Artificial Intelligence in Pulmonary Hypertension: Advancements, Opportunities, and Challenges},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {21},
  pages = {8707},
  doi = {10.3390/jcm15218707}
}
Kostenlos starten →